Stockreport

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Short Stature (ISS), born Small for Gestational Age (SGA), or Noonan Syndrome (NS) Sogroya ® (somapacitan-beco) is a once-weekly treatment option, offering an alternat [Read more]